Pfizer lifts 2026 outlook after Q2 revenue rise

Pfizer (PFE) increased the midpoint of its full-year 2026 revenue guidance by $500 million, setting a new expected range of $60.5 billion to $62.5 billion. The updated outlook reflects about $1.5 billion of stronger-than-expected performance from non-COVID products, partly offset by a lower revenue expectation for COVID-19 products of approximately $4 billion, down from about $5 billion. Management reaffirmed full-year adjusted diluted EPS guidance of $2.80 to $3.00 per share, signaling no change in earnings expectations despite the shift in revenue mix.

The higher guidance follows second-quarter 2026 revenue of $15.03 billion, an increase of about 3% compared with the same quarter a year earlier. Operational strength in launched and acquired, non-COVID medicines was cited as the key driver behind the outlook revision. The company framed the changes as a reflection of durable demand in its core portfolio even as COVID-19 product sales moderate.

For Q2 2026, Pfizer reported adjusted diluted EPS of $0.77, in line with the company’s reiterated full-year earnings framework. Despite this adjusted profitability, Pfizer posted a GAAP net loss of $248 million for the quarter. The loss was driven primarily by approximately $4.3 billion in non-cash intangible asset impairment charges, which weighed on reported results but did not affect adjusted earnings metrics.

In addition to impairment charges, Pfizer disclosed a $650 million acquired in-process research and development charge related to an Innovent Biologics licensing deal. This charge is expected to create an estimated $0.10 headwind to adjusted EPS. The treatment of this item underscores the distinction between GAAP results, which include such one-time and non-cash items, and adjusted figures that investors use to assess underlying performance.

Stronger demand for non-COVID products was central to Pfizer’s quarter. The company estimated that non-COVID products delivered roughly $1.5 billion more revenue than previously expected for 2026, more than offsetting lower expectations for COVID-19 products. This shift indicates that growth in the broader portfolio is increasingly driving the company’s revenue base.

Within this portfolio, Eliquis was singled out as a major contributor. The drug generated about $2.43 billion in revenue during Q2 2026, representing an approximately 19% operational increase. Eliquis was described as a primary factor in the quarter’s outperformance, illustrating the importance of established therapies in Pfizer’s current growth profile.

Alongside its earnings and guidance update, Pfizer announced about $2.5 billion in additional anticipated productivity and manufacturing-related savings. These savings are planned to be realized between 2027 and 2029. The initiative is intended to enhance efficiency and support profitability as the product mix evolves and COVID-19 revenues decline.

Taken together, the revised revenue guidance, strong non-COVID product performance, and new cost-saving targets outline Pfizer’s current financial trajectory. While large non-cash impairment charges and R&D-related expenses weighed on GAAP earnings in the quarter, adjusted results and forward guidance highlight continued confidence in the company’s underlying operations.